

Research papers

Endpoint measures in the *mdx* mouse relevant for muscular dystrophy pre-clinical studies [☆]

Yvonne M. Kobayashi, Erik P. Rader, Robert W. Crawford, Kevin P. Campbell ^{*}

Department of Molecular Physiology and Biophysics, Howard Hughes Medical Institute, University of Iowa Roy J. and Lucille A. Carver College of Medicine, 4283 Carver Biomedical Research Building, 285 Newton Road, Iowa City, IA 52242-1101, USA

Department of Neurology, Howard Hughes Medical Institute, University of Iowa Roy J. and Lucille A. Carver College of Medicine, 4283 Carver Biomedical Research Building, 285 Newton Road, Iowa City, IA 52242-1101, USA

Department of Internal Medicine, Howard Hughes Medical Institute, University of Iowa Roy J. and Lucille A. Carver College of Medicine, 4283 Carver Biomedical Research Building, 285 Newton Road, Iowa City, IA 52242-1101, USA

Received 22 June 2011; received in revised form 20 July 2011; accepted 1 August 2011

Abstract

Loss of mobility influences the quality of life for patients with neuromuscular diseases. Common measures of mobility and chronic muscle damage are the six-minute walk test and serum creatine kinase. Despite extensive pre-clinical studies of therapeutic approaches, characterization of these measures is incomplete. To address this, a six-minute ambulation assay, serum creatine kinase, and myoglobinuria were investigated for the *mdx* mouse, a dystrophinopathy mouse model commonly used in pre-clinical studies. *mdx* mice ambulated shorter distances than normal controls, a disparity accentuated after mild exercise. An asymmetric pathophysiology in *mdx* mice was unmasked with exercise, and peak measurements of serum creatine kinase and myoglobinuria were identified. Our data highlights the necessity to consider asymmetric pathology and timing of biomarkers when testing potential therapies for muscular dystrophy.

© 2011 Elsevier B.V. All rights reserved.

Keywords: *mdx*; Duchenne muscular dystrophy; Biomarkers; Pre-clinical studies; Ambulation

1. Introduction

Duchenne muscular dystrophy (DMD) is caused by mutations in the X-linked dystrophin gene that lead to a complete loss of dystrophin expression in muscle. Loss of

dystrophin expression leads to a decrease in mobility and progressive muscle necrosis in DMD. Initial clinical diagnosis is from the identification of muscle weakness, elevated serum creatine kinase (sCK) or the appearance of myoglobinuria, and a muscle biopsy. A patient endpoint measure commonly used to assess mobility and efficacy of a therapeutic intervention is the six-minute walk test. In pre-clinical studies, common endpoint measures to assess the efficacy of a potential therapy are sCK and histological analysis of muscle pathology. Current treatments that improve endpoint measures in patients are limited. Part of the problem may be the design and interpretation of pre-clinical studies using the *mdx* mouse. This aspect is highlighted in three recent publications, demonstrating publication bias in basic research [1], over-optimistic or biased conclusions from animal models [2], and the need for quality pre-clinical data [3].

[☆] All the authors concur with the submission of this manuscript. This manuscript is approved by the University of Iowa Office of Research. If accepted, this manuscript shall not be published elsewhere in the same form in either the same or any other language, without consent of the Editor or Publisher.

^{*} Corresponding author at: Department of Molecular Physiology and Biophysics, Howard Hughes Medical Institute, University of Iowa Roy J. and Lucille A. Carver College of Medicine, 4283 Carver Biomedical Research Building, 285 Newton Road, Iowa City, IA 52242-1101, USA. Tel.: +1 319 335 7867; fax: +1 319 335 6957.

E-mail address: kevin-campbell@uiowa.edu (K.P. Campbell).

URL: <http://www.physiology.uiowa.edu/campbell/> (K.P. Campbell).

The *mdx* mouse, the animal model commonly used in pre-clinical studies for Duchenne muscular dystrophy, lacks dystrophin due to a point mutation in the dystrophin gene [4]. The *mdx* muscle pathology is similar to young DMD boys, but the clinical course is less severe than older patients. Investigations using the *mdx* mouse have provided insights into the complex mechanisms leading to muscle degeneration, progression of muscle weakness, and clinical presentation of the disease. Our goal for this study was to refine three pre-clinical endpoint measures for the *mdx* mouse: the six-minute ambulation assay, sCK, and myoglobinuria. More accurate pre-clinical endpoint measure for the *mdx* mice, used in conjunction with other refined endpoint measures, will enhance the translatability of pre-clinical data for DMD and possibly other loss of mobility conditions, to the clinic.

2. Materials and methods

2.1. Mice

The Jackson Laboratory mouse strains used in this study: C57BL/6J, B6.129P2-*Nos3*^{tm1Unc}/J, B6.129S4-*Nos1*^{tm1Plh}/J, B6.129P2-*Nos2*^{tm1Lau}/J, and C57BL/10ScSn-*Dmd*^{mdx}/J (abbreviated as C57BL/6, *eNOS*-null, *nNOS*-null, *iNOS*-null, and *mdx*, respectively). Other mice used were: B6.129Sv-*Mb*^{tmDjg} and B6.129Sv-*Utrn*^{tmJrs} (abbreviated as *Mb*-null [5] and *Utrn*-null [6], respectively). *Mb*-null;*mdx*, *mdx*;*iNOS*-null, *mdx*;*nNOS*-null, and *mdx*;*Utrn*-null mice were generated by intercrossing mice to produce mice on a mixed C57BL/6J;C57BL/10ScSnJ background. Phosphodiesterase 5A inhibitor treatment for *mdx* mice was previously described [7]. To limit mild strain differences that could be out bred [8], mice were bred at the University of Iowa to produce a large enough number of mice from the same breeding pair for each cohort of experiments. To minimize gender variation [8], mice were males at 10 weeks old unless otherwise stated, and had food and water *ad libitum* with exposure to the same care handler. Mice were synchronized, group housed, and tested in rooms on the same shifted 12:12-h light:dark cycle. Testing time for all mice was at Zeitgeber time 14–17, when the mice were physiologically awake and active [9]. Mouse housing and activity rooms were under specific pathogen-free conditions. All mouse experiments were performed in accordance with animal usage guidelines and regulations set forth by NIH and the University of Iowa Institutional Animal Care and Use Committee. Mice were maintained within a centralized barrier animal facility at the University of Iowa directed by the Office of Animal Resources.

2.2. Six-minute ambulation distance test

Mouse activity was monitored using the VersaMax Animal Activity Monitoring System as previously described [7]. Mice were tested in individual chambers, for 6 × 1 minute intervals before and immediately after

exercise. Data were transferred to a Microsoft Excel worksheet and calculations were done within the Excel program. For each minute of ambulation, the average total distance was determined and standard errors were calculated. The cumulative distance per minute up to 6 min and the standard error for each minute were charted.

2.3. Magnetic resonance imaging (MRI)

Mice were anesthetized using a mixture of ketamine and xylazine (87.5 and 12.5 mg/kg, I.P.), and the plane of anesthesia was confirmed by absence of the pedal reflex. For scans done after exercise, imaging started less than 10 min after exercise to allow for mice to be anesthetized. Images were captured in the axial and coronal planes with a Varian Unity/Inova 4.7 T small-bore MRI system (Varian, Palo Alto, CA), using an acquisition consisting of T₂-weighted fast spin-echo sequence (TR/TE = 5000/48 ms) with in-plane resolution of 0.11 × 0.22 mm and slice thickness of 0.6 mm.

2.4. Treadmill exercise

Mice were mildly exercised with an adjustable variable-speed belt treadmill from AccuPacer as previously described [7].

2.5. Contractile properties of isolated muscle

Contractile properties were measured for isolated male *mdx* extensor digitorum longus muscles from five unexercised or five post-exercised mice ages 16–19 weeks. Measurements post-exercise were done within 15–30 min after exercise. Mice were anesthetized with an intra-peritoneal injection of 1.3% avertin (0.015 ml/g body weight) and muscles removed. The proximal tendon was clamped to a post and the distal tendon was tied to a dual mode servomotor (Aurora Scientific) with 6–0 suture. Contractile properties, optimal fiber length and maximal isometric tetanic force, were determined as previously described [10]. The lengthening contraction protocol (LCP) was previously described [11]. The force deficit was defined as the difference between pre- and post-LCP force expressed as a percentage of pre-LCP force [11]. *P*-value calculations were made using a Student *t* test.

2.6. Serum creatine kinase assay

Serum CK levels before and after exercise were measured as previously described [7]. For this study, blood collection and assays were done at designated time points. To reduce variability in data sets [8], all mice used were male, from the same breeding colony, and of the same age. The groups of mice tested for Fig. 3A, F, G were from different breeding colonies. Normal sCK levels were 100–500 U/l. Elevated sCK levels were greater than 500 U/l and hyperCKemia values were considered greater than 20,000 U/l. For

blood collection, mice were placed in a restrainer, which they freely walked out of after blood collection. The initial drop of blood after the tail vein nick was wiped away and the subsequent 25 μ l of blood was collected without tail manipulation. Serum was diluted 1:9 and 1:49 (v:v), to ensure activity levels within the limits of the assay, and assayed in triplicate. There was a minimum of 24 h between blood collections from the same mouse. For sCK at different intervals, sCK from eight sets of *mdx* mice were measured 24 h prior to exercise. On test day (0d), all eight sets of mice were exercised and sCK was assayed 2 h post-exercise; 24 h following the initial exercise, the 1d set of *mdx* mice were run again and sCK was assayed; the same procedure was followed for all other groups for subsequent interval days after the initial run. For sCK at different intervals within a 120-minute time frame after exercise, nine sets of mice were used with each set of mice representing a time point.

2.7. Urine collection and dip stick assay

Urine was collected from each mouse by allowing mice to urinate over a fresh piece of aluminum foil. Voided urine was transferred to a fresh microcentrifuge tube, the color noted, and tested immediately. Urine was applied to the reagent strip (Siemens Multistix[®] 10SG) in which the development of a blue color indicated high levels of a heme protein. None of the mice had hematuria.

2.8. Evans Blue Dye uptake imaging and quantification

Evans Blue Dye (EBD) injection was described previously [12]. After 3 h, mice were run on a treadmill. Mice were sacrificed and quadriceps and gastrocnemius muscles were collected. Axial 7 μ m cryo-sections of skeletal muscle were visualized [12]. For quantification, each muscle was placed in 1 ml of *N,N*-dimethyl formamide for 48 h to extract the EBD. Absorbance of EBD in each solution was measured at 630 nm. Values were normalized by dividing by the weight of the tissue.

2.9. Statistical analysis

Unless otherwise stated, the data were calculated according to an analysis of variance. *P*-value calculations were made using a Student *t* test. Data are expressed as mean \pm SEM. See Table S1 for values, averages, and SEM for ambulation.

3. Results

3.1. Ambulation distance within 6 min to measure *mdx* mouse performance

We combined and adapted the step-activity monitor and six-minute walk test in the form of a six-minute ambulation distance assay to assess mouse performance (Fig. 1).

Comparing basal ambulatory performance over 6 min, we found that *mdx* mice show less ambulatory distance over 6 min than normal wild-type mice (Fig. 1A). This difference in ambulation performance between *mdx* and wild-type mice parallels that of DMD and control boys in the six-minute walk test [13]. Since ambulatory DMD boys are not sedentary like normally housed *mdx* mice, we ensured the clinical relevance of the ambulatory assay by physically challenging the mice before measuring their ambulatory performance. As ambulatory DMD boys do not perform hard activities to exhaustion, the *mdx* mice were challenged with mild and limited treadmill exercise, as previously described [7], before ambulation was assessed. We chose this mild, limited exercise as opposed to an exhaustive protocol, during their physiologically active time, to assay performance of active mice, and not that of muscle fatigued mice. C57BL/6 mice showed no significant difference in ambulation before and after exercise. However, with exercise, ambulation of *mdx* mice was affected and the difference between wild-type and *mdx* mouse ambulation distance was accentuated (Fig. 1B). These ambulation data clearly demonstrate a distinction between control and *mdx* mouse performance, particularly after mild exercise.

To validate the ambulation assay, we tested post-exercise performance of other mouse models used to examine pathogenic mechanisms of dystrophin deficiency. Constitutively active endothelial and neuronal nitric oxide synthase (eNOS and nNOS, respectively) enzymes play important roles in vasomodulation, but only genetic deletion of nNOS in mice leads to *mdx*-like debility after mild exercise [7]. Basal ambulation distances of *eNOS*-null were similar to that of wild-type mice (Fig. S1A). This similarity is consistent with the indistinguishable pre-exercise vertical activity between wild-type and *eNOS*- and *nNOS*-null mouse strains [7]. Post-exercise, however, only *nNOS*-null mice displayed reduced ambulation (Fig. 1C). Previous reports show that genetic ablation of nNOS in *mdx* mice does not alter *mdx* muscle pathology [14,15] and that the induction of iNOS expression in *mdx* mice contributes to muscle fiber damage [16,17]. Comparative ambulation distances from wild-type, *mdx*, *mdx*;*iNOS*-null, and *mdx*;*nNOS*-null mice demonstrated that genetic ablation of iNOS or nNOS decreased *mdx* performance after exercise (Fig. 1D), but had little effect on the basal ambulation of *mdx* mice (Fig. S1B). Our results from comparing *mdx* and *mdx*;*nNOS*-null ambulation is consistent with our data comparing pre- and post-exercise activity of the same mice, which demonstrated that nNOS perturbation affects performance [7]. Despite reports that *mdx*;*iNOS*-null muscle have less muscle damage [17], their reduced ambulation compared to *mdx* mice was consistent with increased muscle pathology in 6- and 10-week old *mdx*;*iNOS*-null mice (Fig. S2). The *mdx*;*Utrn*-null mice showed significant loss of ambulation after mild exercise (Fig. 1E), consistent with their more severe muscle pathology [18]. Lastly, since we previously found that phosphodiesterase 5A inhibition was able to improve post-exercise vertical activity [7], we




Fig. 1. Six-minute ambulation distance as an endpoint measure in pre-clinical investigations for DMD. An ambulation distance assay was developed by adapting the step-activity and six-minute walk tests for mice using an open field activity chamber. (A) Basal ambulation distances versus time of C57BL/6 and *mdx* mice were charted. Ambulation distances were charted after mice were challenged with mild exercise (B, C, D, E, and F). (B) C57BL/6 versus *mdx* mice. (C) C57BL/6 versus *eNOS*- and *nNOS*-null mice. (D) C57BL/6 versus *mdx*, *mdx;iNOS*-null and *mdx;nNOS*-null mice. (E) *mdx* versus *mdx;Utrn*-null mice. (F) C57BL/6 versus *mdx* treated with phosphodiesterase 5A inhibitor and untreated *mdx* mice ($n = 6$ for *mdx*, C57BL/6, *nNOS*-null, *eNOS*-null mice, and *mdx + PDE5Ai*; $n = 4$ for *mdx;nNOS*-null, *mdx;Utrn*-null, and *mdx;iNOS*-null mice. Error bars indicate SEM).

compared post-exercise ambulation distance of control and *mdx* mice to that of *mdx* mice pre-treated with phosphodiesterase 5A inhibitor (Fig. 1F). Phosphodiesterase 5A inhibitor treatment improved *mdx* mouse ambulation. These data demonstrate that the six-minute ambulation assay is a highly responsive test of disease severity and functional response with *mdx* mice.

3.2. Bilateral analysis of *mdx* hind leg skeletal muscles and asymmetric pathology

When *mdx* mice were treadmill exercised, each *mdx* mouse, unlike wild-type controls, consistently leaned to one side of the treadmill. Notably, *mdx* mice subjected to multiple rounds of treadmill exercise leaned to the same side for each run suggesting that dystrophin deficiency causes asymmetric skeletal muscle pathology or weakness. To test this, we performed T₂-weighted MRI of wild-type and *mdx* mouse hind quarters, without exercise and after mild exercise (Fig. 2A). Post-exercise changes in

T₂-weighted MRI show up as lighter areas on scans and indicate changes in water content, which represent muscle edema or inflammation. Coronal MRI scans of wild-type hind leg muscles showed no T₂-weighted changes (Fig. 2A, wild-type panels). Coronal MRI scans of *mdx* mice without exercise showed no T₂-weighted changes, except some mice showed small areas of fibrosis (Fig. 2A, *mdx* no-ex, small arrowheads). Coronal images of the same *mdx* mice all showed a large increase in T₂-weighted changes after exercise (Fig. 2A, *mdx* post-ex, large arrowheads) that were always more in one leg than the contralateral leg, even in older *mdx* mice (Fig. S3).

The leaning and sometimes unilateral appearance of T₂-weighted changes in *mdx* hind leg muscles suggested asymmetric pathology and weakness. We examined *mdx* muscle damage by EBD. Damaged or necrotic muscle fibers stain positive for endogenous extracellular proteins like albumin or IgG/M [4]. EBD binds albumin. In unexercised *mdx* mice, muscle fibers that stain positive for EBD are also the ones that are positive for albumin or mouse




Fig. 2. Asymmetric pathology of *mdx* mice. (A) Representative coronal magnetic resonance imaging scans of wild-type and *mdx* mouse hind quarters. Scans shown for *no-ex* and *post-ex* are from the same mouse. Localized areas of fibrosis (small white arrows) are detectable in *mdx* mice. T_2 -weighted changes (large white arrows) from *mdx* mice are indicative of muscle edema or inflammation ($n = 5$ for each). (B) Representative microscope images from bilateral analysis of quadriceps muscles (*quads*) and gastrocnemius muscles (*gastrocs*) from *mdx* mice post-exercise. Areas of Evans Blue Dye uptake into damaged muscle fibers (white arrows) and side the mouse leaned on are noted ($n = 6$). (C) Four *mdx* mice were I.V. injected with Evans Blue Dye then subjected to mild exercise. Quadriceps (*quad*) and gastrocnemius (*gastroc*) muscles were isolated separately. Total Evans Blue Dye was quantified for each muscle isolated. Measurements were done in triplicate, error bars are *SEM*. (D) Absolute differences in percent force deficits between left and right *mdx* extensor digitorum longus muscles. Error bars are *SEM*. (*) Significant difference ($P = 0.012$) was observed between values for exercised mice compared with those of non-exercised mice.

IgG/M [12,19]. Thus, detection of EBD uptake into skeletal muscle is an accurate index of muscle pathology. To test asymmetric muscle pathology with *mdx* mice, we performed bilateral examination of EBD staining in *mdx* quadriceps and gastrocnemius muscles after exercise (Fig. 2B). We found that EBD detection in the quadriceps and gastrocnemii muscles was asymmetric in every mouse tested; in some cases, only one side featured detectable

EBD/albumin uptake into muscle (Fig. S3). Quantitatively, total EBD measurements confirmed variable EBD uptake from each *mdx* mouse and asymmetrical EBD uptake in *mdx* quadriceps and gastrocnemius muscles after exercise (Fig. 2C). To test if this asymmetrical pathology translated to asymmetrical muscle contractile properties, we compared the susceptibility to contraction-induced injury between the right and left muscles of *mdx* mice (Fig. 2D).

For mice without exercise and mice after exercise, isolated extensor digitorum longus muscles were exposed to a lengthening contraction protocol and force deficit was determined. Exercise heightened the disparity between right and left muscles for susceptibility to injury. With exercise, the more injury-prone muscles of each mouse incurred force deficits of $50 \pm 4\%$ which were typically two-fold greater than the force deficits of the contra-lateral muscles, which averaged $31 \pm 3\%$. Thus, post-stretch force deficits were also asymmetric in *mdx* mice.

3.3. Timing of indices of muscle pathology in *mdx* mice

Each time *mdx* exercised, they leaned to the same side. However, repeating the exercise did not significantly affect the post-exercise ambulation performance (Fig. 3A). This lack of alteration in ambulation after a repeated exercise suggested that there was no further muscle damage occurring. To test this, we first investigated indices of muscle damage and necrosis by determining the peak analysis time for sCK in wild-type and *mdx* mice after exercise (Fig. 3B). We found that sCK levels from *mdx* mice were generally elevated above control mouse levels without exercise (Fig. 3B, 4903.09 ± 443.76 U/l). After exercise, sCK consistently peaked to hyperCKemia levels 2 h after exercise (Fig. 3B, $55,850.77 \pm 5523.04$ U/l) and gradually dissipated to below pre-exercise sCK levels (Fig. 3B, 565.45 ± 200.66 U/l) by 24 h. With wild-type mice, sCK readings were consistently below 500 U/l with a slight peak 1 h post-exercise. Wild-type sCK activity readings went below pre-exercise levels by 6 h.

We assayed the urine of *mdx* mice pre- and post-exercise using urine dipsticks (Fig. 3C). Similar to the pattern of sCK post-exercise, heme detection in *mdx* urine peaked 2 h post-exercise and dissipated by 6 h, with no evidence of heme in the urine by 24 h post-exercise. To determine which heme protein the dipstick test was detecting, we crossed myoglobin-null (*Mb*-null) [5] and *mdx* mice, then tested *Mb*-null;*mdx* mouse sCK and urine after mild exercise (Fig. 3D, E). *Mb*-null;*mdx* were negative for the presence of heme in their urine post-exercise, but had elevated sCK before exercise and hyperCKemia post-exercise. Thus, a positive result on urine dipsticks from *mdx* mice indicates that *mdx* mice have exercise-induced myoglobinuria, which corresponded with hyperCKemia levels.

Consistent with no significant change in *mdx* ambulation performance, *mdx* sCK levels did not increase as it did during the initial exercise. We repeated the mild exercise with different sets of *mdx* mice at 1, 3, 5, 7, 9, 11, 13, and 14 days after the initial exercise, and measured sCK at the 2 h time point (Fig. 3F). After the rise in sCK to hyperCK levels following the first bout of exercise on day 0 (0d), sCK from the *mdx* mice rose to that same level only when the interval between exercise was 14 days. Myoglobinuria followed the same pattern (Fig. 3F, inset).

To test for early peaking of sCK, we exercised *mdx* mice twice in a 24 h interval, and collected sCK at several time

points up to 2 h following the second bout of exercise (Fig. 3G). Twenty-four hours since an initial mild exercise, different sets of *mdx* mice were mildly exercised again and sCK was measured at time intervals post-exercise (0, 15, 30, 45, 60, 75, 90, 105, and 120 min). Different sets of mice were used for each time point. Readings for sCK remained relatively close to elevated pre-exercise levels within each time point, consistent with ongoing regeneration. At the 2 h mark, sCK readings were the lowest. Myoglobinuria was undetectable during this 2 h analysis (Fig. 3G, inset).

4. Discussion

The *mdx* mouse is extensively used as the pre-clinical animal model for dystrophin deficiency to investigate therapeutic approaches for DMD. There are promising therapeutic interventions emerging for DMD that are in Phase I/II clinical trials like exon skipping, myostatin, and compounds that up-regulate utrophin [20]. Despite these recent advances, there are a multitude of potential therapies that have not succeeded in clinical trials, currently leaving patients with no curative treatment. This discrepancy has caused researchers to question the *mdx* mouse as a model for DMD as well as the validity of translating promising results from *mdx* pre-clinical studies into clinical trials. Our data demonstrate that when properly assayed, the *mdx* mouse is an ideal model for pre-clinical studies for DMD.

A six-minute ambulation test was designed for mice as an endpoint measure for DMD pre-clinical studies. Timed sub-maximal exercise performance is used as a standard outcome measure in clinical trials to test the efficacy of a treatment on improving mobility. This mild exercise is used for a variety of diseases in which patients experience physical limitations. The step-activity monitor and six-minute walk test are two forms of this kind of testing that are used with normal and ambulatory DMD boys [13,21]. We combined these two assays into the six-minute ambulation distance test for mice. Like with DMD boys, *mdx* mice showed reduced ambulation. The reduced ambulation of the *mdx*;*iNOS*-null mouse was a surprise, but not so when we found that the muscles were consistently more fibrotic than *mdx* muscles. Our *mdx*;*iNOS*-null data suggest that some iNOS activity is necessary during the degeneration-regeneration of dystrophic muscle to prevent extensive muscle fibrosis. The reduced ambulation of the *mdx*;*nNOS*-null mice after mild exercise is in line with our previous findings of lower post-exercise vertical activity with these mice [7], and is also consistent with a report that shows myopathic functional deficits with reduced bulk and impaired contractile function in nNOS-deficient muscle [22]. The increased performance in the six-minute ambulation assay of *mdx* mice treated with phosphodiesterase 5A inhibitor was consistent with our previous data that this acute pre-treatment increases *mdx* post-exercise vertical activity [7]. This pharmacological treatment along with the other *mdx* mouse models used in this study validated the six-minute ambulation assay as a




Fig. 3. Post-exercise ambulation, serum creatine kinase (sCK), and myoglobinuria. (A) Six-minute ambulation distance post-exercise and after a repeated exercise 24 h later ($n = 4$). (B) Serum CK from C57BL/6 and *mdx* mice before (*pre*) and at different time points after exercise ($n = 4$ for each). (C) The presence of heme in the urine was assessed using urine dipsticks. Key for heme amounts is displayed ($n = 3$ for each). (D) Urine collected pre- and post-exercise from littermate *mdx* and *Mb-null;mdx* mice were tested on dipstick strips ($n = 3$ per analysis). (E) Serum CK before and 2 h after exercise from *Mb-null;mdx* mice ($n = 4$). (F) After an initial bout of exercise, eight sets of *mdx* mice, at different intervals (1d, 3d, 5d, 7d, 9d, 11d, 13d, and 14d), were re-exercised and sCK was measured (0d $n = 40$, 1d $n = 5$, 3d $n = 5$, 5d $n = 6$, 7d $n = 4$, 9d $n = 4$, 11d $n = 3$, 13d $n = 6$, and 14d $n = 7$), and myoglobinuria was tested (inset). (G) Nine sets of *mdx* mice were exercised and then 24 h later were exercised again. Each set of mice represented a time point. Serum CK was assayed at $T = 0, 15, 30, 45, 60, 75, 90, 105,$ and 120 min after the repeated exercise. ($T = 0, n = 11$; $T = 15, n = 6$; $T = 30, 45,$ and $60, n = 6$; $T = 75, 90, 105,$ and $120, n = 4$), and myoglobinuria was tested with representative results in the inset. Error bars are SEM.

performance outcome measure for DMD pre-clinical studies using the *mdx* mouse. In addition, we demonstrated that after mild exercise with the *mdx* mouse, this assay is responsive to varying degrees of muscle pathology in that ambulation increased or decreased with known changes in muscle function among the different *mdx* mouse models and with a pharmacological treatment.

The combination of the exercise and ambulation assay provided several informative pieces of data. The reduced ambulation with *mdx* mice is in agreement with previous studies that show *mdx* mice have reduced locomotor activity based on a SHIRPA test [23] and reduced voluntary running compared to their wild-type counterparts [24–27]. Even the leaning of *mdx* mice during exercise on the treadmill was not too surprising since it is similar to what

ambulatory DMD boys do to maintain balance and gait while walking [28]. What was important to this observation of leaning to one side of the treadmill was that we did bilateral analysis of muscle pathology and found *mdx* mice have asymmetric muscle pathology in their quadriceps and gastrocnemius skeletal muscles and have asymmetric muscle force. These findings are significant, as several therapeutic studies for DMD use muscle pathology as an endpoint measure, and many therapeutic pre-clinical studies test one leg of an *mdx* mouse and use the contra-lateral leg as a control.

The asymmetric *mdx* muscle pathology may be similar to the variability in dystrophinopathy patients, with some muscles being affected while neighboring, or other muscles being spared from pathology. Like with humans, mice have a

lateral preference [29], i.e. display handedness, but in generally, most mouse strains show an equal distribution of right- and left-handedness [30,31]. Whether this laterality influences *mdx* physiopathology and susceptibility to contraction-induced injury or muscle pathology influences the laterality of *mdx* mice, remains unknown. Innate laterality could influence *mdx* pathology, whereby the dominant side gets more use than the other and eventually becomes more severely affected. Conversely, asymmetric *mdx* muscle pathology could influence laterality. Clinically, muscle weakness in DMD patients is often described as symmetric, in that both left and right sides will show muscle weakness. However, DMD patients do have asymmetric muscle weakness. The weakness is symmetrical in that both sides show muscle weakness, but the degree of left to right weakness may be variable. The variability could be due to handedness or to a learned adaptive response. Whether there is asymmetric muscle pathology with DMD patients is unknown as systematic bilateral analysis of skeletal muscle would require multiple muscle biopsies that would be difficult to ethically justify. Nevertheless, our findings demonstrate that asymmetric muscle pathology as well as asymmetric weakness should be considered when taking biopsies for testing therapies in animal models, particularly the *mdx* mouse.

The ongoing necrosis of skeletal muscle and the asymmetric pathology and weakness could contribute to the reduced ambulation and leaning during exercise of *mdx* mice. If an *mdx* mouse leaned to one side during the treadmill exercise, the same mouse would lean to the same side when the treadmill exercise was repeated. In addition, repeating the exercise with the same mouse the next day did not significantly affect the post-exercise ambulation performance. Consistent with no change in ambulation performance, *mdx* sCK levels did not increase as it did during the initial exercise. Despite each skeletal muscle fiber being susceptible to contraction-induced injury due to the lack of dystrophin, and chronic inflammation in the *mdx* mouse [32], this lack of increase in sCK after subsequent exercise suggested that repeat exercise does not result in further muscle damage. The release of CK and myoglobin from normal muscle, however, is thought to activate an inflammatory response that enhances clearance of these proteins, such that subsequent muscle damage fails to give rise to elevated muscle-cell proteins in the blood [33–35]. We found no evidence of sCK or myoglobinuria peaking sooner. It is not clear why biomarkers of muscle damage follow this pattern. Nevertheless, our data demonstrate the importance of mouse activity and analysis time for these muscle damage biomarkers. If the normally sedentary *mdx* mouse is active one to fourteen days before a sCK analysis, sCK levels will likely be lower than expected when analyzed. Thus, a low sCK reading in an *mdx* mouse pre-clinical study may not be a response to the therapeutic agent, but simply a reflection of mouse activity during the trial period.

In summary, we present the use of a six-minute ambulation test, in conjunction with refined analyses of muscle pathology and biomarkers of muscle damage, as

pre-clinical endpoint measures relevant for muscular dystrophy pre-clinical trials using *mdx* mice. Future pre-clinical study designs for muscular dystrophy should take into account possible baseline asymmetry of muscle pathology. Our data is consistent with other reports that describe physiological function being altered after performance testing with *mdx* mice [23], thus sCK levels can also be affected by pre-sCK assessment exercise and/or activity. Therefore, future study designs should consider the circadian rhythm and mouse activity in mouse physiological performance analyses before muscle damage biomarkers are assayed. Positive findings using these endpoint measures may enhance the translatability of future pre-clinical studies for Duchenne and other muscular dystrophies.

Acknowledgments

We thank M.G. Anderson, S.A. Moore, and R.K. Shields for comments, and K. Garringer, M.J. Schneider, and S.J. Prouty for technical assistance. We thank D.J. Garry (University of Minnesota) for the *Mb*-null mice and J.R. Sanes (Harvard Medical School) for the *Utrn*-null mice. This work was supported in part by a Paul D. Wellstone Muscular Dystrophy Cooperative Research Center Grant (NINDS/U54-NS053672). Y.M.K. was supported by an NIH/National Research Service Award (NRSA) Training Fellowship from the University of Iowa Cardiovascular Interdisciplinary Research (NHLBI/T32 HL07121), an individual NRSA Fellowship (NIAMS/F32-AR48742), an NIAMS/R01-AR051199, a Senator Paul D. Wellstone Fellowship (NINDS/U54-NS053672-S), an American Recovery and Reinvestment Act grant (NIAMS/R01-AR051199-S) and an Institute for Clinical and Translation Science Pilot Grant Award (NCRRL/UL1-RR0024979). E.P.R. was supported by a Muscular Dystrophy Association Development Grant (67814). K.P.C. is an Investigator of the Howard Hughes Medical Institute. All authors revised the manuscript and gave final approval for the version to be published. The authors declare no competing financial interests.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at [doi:10.1016/j.nmd.2011.08.001](https://doi.org/10.1016/j.nmd.2011.08.001).

References

- [1] Sena ES, van der Worp HB, Bath PM, Howells DW, Macleod MR. Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. *PLoS Biol* 2010;8:e1000344.
- [2] van der Worp HB, Howells DW, Sena ES, et al. Can animal models of disease reliably inform human studies? *PLoS Med* 2010;7:e1000245.
- [3] London AJ, Kimmelman J, Emborg ME. Research ethics. Beyond access vs. protection in trials of innovative therapies. *Science* 2010;328:829–30.

- [4] Blake DJ, Weir A, Newey SE, Davies KE. Function and genetics of dystrophin and dystrophin-related proteins in muscle. *Physiol Rev* 2002;82:291–329.
- [5] Garry DJ, Ordway GA, Lorenz JN, et al. Mice without myoglobin. *Nature* 1998;395:905–8.
- [6] Grady RM, Merlie JP, Sanes JR. Subtle neuromuscular defects in utrophin-deficient mice. *J Cell Biol* 1997;136:871–82.
- [7] Kobayashi YM, Rader EP, Crawford RW, et al. Sarcolemma-localized nNOS is required to maintain activity after mild exercise. *Nature* 2008;456:511–5.
- [8] Spurney CF, Gordish-Dressman H, Guerron AD, et al. Preclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measures. *Muscle Nerve* 2009;39:591–602.
- [9] Thompson S, Lupi D, Hankins MW, Peirson SN, Foster RG. The effects of rod and cone loss on the photic regulation of locomotor activity and heart rate. *Eur J Neurosci* 2008;28:724–9.
- [10] Brooks SV, Faulkner JA. Contractile properties of skeletal muscles from young, adult and aged mice. *J Physiol* 1988;404:71–82.
- [11] Wang R, Urso ML, Zambraski EJ, Rader EP, Campbell KP, Liang BT. Adenosine A(3) receptor stimulation induces protection of skeletal muscle from eccentric exercise-mediated injury. *Am J Physiol Regul Integr Comp Physiol* 2010;299:R259–67.
- [12] Straub V, Rafael JA, Chamberlain JS, Campbell KP. Animal models for muscular dystrophy show different patterns of sarcolemmal disruption. *J Cell Biol* 1997;139:375–85.
- [13] McDonald CM, Henricson EK, Han JJ, et al. The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. *Muscle Nerve* 2010;41:500–10.
- [14] Chao DS, Silvagno F, Bredt DS. Muscular dystrophy in mdx mice despite lack of neuronal nitric oxide synthase. *J Neurochem* 1998;71:784–9.
- [15] Crosbie RH, Straub V, Yun HY, et al. Mdx muscle pathology is independent of nNOS perturbation. *Hum Mol Genet* 1998;7:823–9.
- [16] Bellinger AM, Reiken S, Carlson C, et al. Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle. *Nat Med* 2009;15:325–30.
- [17] Villalta SA, Nguyen HX, Deng B, Gotoh T, Tidball JG. Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy. *Hum Mol Genet* 2009;18:482–96.
- [18] Grady RM, Teng H, Nichol MC, Cunningham JC, Wilkinson RS, Sanes JR. Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: a model for Duchenne muscular dystrophy. *Cell* 1997;90:729–38.
- [19] Wooddell CI, Zhang G, Griffin JB, Hegge JO, Huss T, Wolff JA. Use of Evans blue dye to compare limb muscles in exercised young and old mdx mice. *Muscle Nerve* 2010;41:487–99.
- [20] Pichavant C, Aartsma-Rus A, Clemens PR, et al. Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. *Mol Ther* 2011;19:830–40.
- [21] McDonald CM, Widman LM, Walsh DD, Walsh SA, Abresch RT. Use of step activity monitoring for continuous physical activity assessment in boys with Duchenne muscular dystrophy. *Arch Phys Med Rehabil* 2005;86:802–8.
- [22] Percival JM, Anderson KN, Gregorevic P, Chamberlain JS, Froehner SC. Functional deficits in nNOSmu-deficient skeletal muscle: myopathy in nNOS knockout mice. *PLoS One* 2008;3:e3387.
- [23] Rafael JA, Nitta Y, Peters J, Davies KE. Testing of SHIRPA, a mouse phenotypic assessment protocol, on Dmd(mdx) and Dmd(mdx3cv) dystrophin-deficient mice. *Mamm Genome* 2000;11:725–8.
- [24] Buyse GM, Van der Mieren G, Erb M, et al. Long-term blinded placebo-controlled study of SNT-MC17/idebenone in the dystrophin deficient mdx mouse: cardiac protection and improved exercise performance. *Eur Heart J* 2009;30:116–24.
- [25] Carter GT, Wineinger MA, Walsh SA, Horasek SJ, Abresch RT, Fowler Jr WM. Effect of voluntary wheel-running exercise on muscles of the mdx mouse. *Neuromuscul Disord* 1995;5:323–32.
- [26] Dupont-Versteegden EE, McCarter RJ, Katz MS. Voluntary exercise decreases progression of muscular dystrophy in diaphragm of mdx mice. *J Appl Physiol* 1994;77:1736–41.
- [27] Wineinger MA, Abresch RT, Walsh SA, Carter GT. Effects of aging and voluntary exercise on the function of dystrophic muscle from mdx mice. *Am J Phys Med Rehabil* 1998;77:20–7.
- [28] Gaudreault N, Gravel D, Nadeau S, Houde S, Gagnon D. Gait patterns comparison of children with Duchenne muscular dystrophy to those of control subjects considering the effect of gait velocity. *Gait Posture* 2010;32:342–7.
- [29] Collins RL. On the inheritance of handedness. I. Laterality in inbred mice. *J Hered* 1968;59:9–12.
- [30] Signore P, Chaoui M, Nosten-Bertrand M, Perez-Diaz F, Marchaland C. Handedness in mice: comparison across eleven inbred strains. *Behav Genet* 1991;21:421–9.
- [31] Signore P, Nosten-Bertrand M, Chaoui M, Roubertoux PL, Marchaland C, Perez-Diaz F. An assessment of handedness in mice. *Physiol Behav* 1991;49:701–4.
- [32] Acharyya S, Villalta SA, Bakkar N, et al. Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. *J Clin Invest* 2007;117:889–901.
- [33] Black CD, McCully KK. Muscle injury after repeated bouts of voluntary and electrically stimulated exercise. *Med Sci Sports Exerc* 2008;40:1605–15.
- [34] Hyatt JP, Clarkon PM. Creatine kinase release and clearance using MM variants following repeated bouts of eccentric exercise. *Med Sci Sports Exerc* 1998;30:1059–65.
- [35] Marqueste T, Giannesini B, Fur YL, Cozzone PJ, Bendahan D. Comparative MRI analysis of T2 changes associated with single and repeated bouts of downhill running leading to eccentric-induced muscle damage. *J Appl Physiol* 2008;105:299–307.